Keyword: Summit Therapeutics
Despite posting promising early data, Summit Therapeutics' Duchenne muscular dystrophy drug missed its primary and secondary endpoints in a phase 2 trial.
The latest analysis links the utrophin modulator to a statistically significant decline in muscle inflammation in boys with DMD.
Sarepta expects to resume dosing in a U.K. trial of its DMD drug golodirsen pending MHRA approval.
Alexion bids farewell to CFO, CCO, R&D head and HR chief; Illumina's interim CCO became permanent; INC Research unveiled new executive team.
Buoyed by its recent, and controversial, FDA approval for its Duchenne drug Exondys 51 (eteplirsen), Sarepta has signed a pact potentially worth more than half a billion dollars with the U.K.’s Summit Therapeutics, giving it rights to its Duchenne candidate in Europe and elsewhere.